Cargando…

Management of Small Cell Carcinoma of Esophagus in China

PURPOSE: Small cell carcinoma of esophagus (SCEC) is characterized by high malignancy and early metastasis. Although the morbidity of SCEC is very low, few studies of patients with SCEC have been conducted in China, there are no sufficient studies of SCEC conducted and reported in the existing publi...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Xu-jing, Luo, Ju-dong, Ling, Yang, Kong, Ying-Ze, Feng, Li-Li, Zhou, Jian, Wang, Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer-Verlag 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3674337/
https://www.ncbi.nlm.nih.gov/pubmed/23609140
http://dx.doi.org/10.1007/s11605-013-2204-7
_version_ 1782272355001696256
author Lu, Xu-jing
Luo, Ju-dong
Ling, Yang
Kong, Ying-Ze
Feng, Li-Li
Zhou, Jian
Wang, Feng
author_facet Lu, Xu-jing
Luo, Ju-dong
Ling, Yang
Kong, Ying-Ze
Feng, Li-Li
Zhou, Jian
Wang, Feng
author_sort Lu, Xu-jing
collection PubMed
description PURPOSE: Small cell carcinoma of esophagus (SCEC) is characterized by high malignancy and early metastasis. Although the morbidity of SCEC is very low, few studies of patients with SCEC have been conducted in China, there are no sufficient studies of SCEC conducted and reported in the existing published works, and the choices of treatment remain controversial. In this work, we aim to study the clinical characteristics of SCEC, and explore the corresponding treatment and prognosis through retrospective analysis. MATERIAL AND METHODS: The original articles were identified through the leading digital libraries in China in which the terms “esophagus or esophageal” and “small cell esophageal carcinoma” appeared from 2005 to 2009, 1,176 eligible cases were reviewed for clinical data. Analysis of survival was conducted using the Kaplan–Meier method, and differences were compared using the log-rank test. RESULTS: One thousand one hundred seventy-six eligible cases were analyzed; the median age of patients was 57 years, with a male-to-female ratio of 2.4:1. The number of SCEC accounted for 1.26 % of esophageal cancer treated in the same period. Of the tumors, 89.7 % were located in mid- and lower thoracic esophagus. The average tumor length was 5.4 cm (0.5–17 cm). The median overall survival was 11.1 months for all patients. The 1-, 2-, 3-, and 5-year average overall survival rates of 469 patients was 51.1, 25.5, 13.2, 7.9 %, respectively. The median survival time for LD patients who received systemic treatment was 16.8 m, whereas for those who received local treatment (surgery), the median survival time was 10.1 m; the median survival time for ED patients who received systemic treatment was 7.4 m, compared with 5.8 m for those who received sole treatment (chemotherapy or radiotherapy). CONCLUSIONS: SCEC is a tumor characterized by high malignancy and early metastasis. Although our retrospective analysis cannot provide definitive conclusions on the optimal treatment modality for SCEC, however, our results suggest that systemic treatment combined with surgical resection plays a major role in the therapy of SCEC, systemic therapy may be an effective approach for the treatment of SCEC, and randomized, prospective, multicenter studies are needed to identify optimal treatment modalities for SCEC
format Online
Article
Text
id pubmed-3674337
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Springer-Verlag
record_format MEDLINE/PubMed
spelling pubmed-36743372013-06-10 Management of Small Cell Carcinoma of Esophagus in China Lu, Xu-jing Luo, Ju-dong Ling, Yang Kong, Ying-Ze Feng, Li-Li Zhou, Jian Wang, Feng J Gastrointest Surg Original Article PURPOSE: Small cell carcinoma of esophagus (SCEC) is characterized by high malignancy and early metastasis. Although the morbidity of SCEC is very low, few studies of patients with SCEC have been conducted in China, there are no sufficient studies of SCEC conducted and reported in the existing published works, and the choices of treatment remain controversial. In this work, we aim to study the clinical characteristics of SCEC, and explore the corresponding treatment and prognosis through retrospective analysis. MATERIAL AND METHODS: The original articles were identified through the leading digital libraries in China in which the terms “esophagus or esophageal” and “small cell esophageal carcinoma” appeared from 2005 to 2009, 1,176 eligible cases were reviewed for clinical data. Analysis of survival was conducted using the Kaplan–Meier method, and differences were compared using the log-rank test. RESULTS: One thousand one hundred seventy-six eligible cases were analyzed; the median age of patients was 57 years, with a male-to-female ratio of 2.4:1. The number of SCEC accounted for 1.26 % of esophageal cancer treated in the same period. Of the tumors, 89.7 % were located in mid- and lower thoracic esophagus. The average tumor length was 5.4 cm (0.5–17 cm). The median overall survival was 11.1 months for all patients. The 1-, 2-, 3-, and 5-year average overall survival rates of 469 patients was 51.1, 25.5, 13.2, 7.9 %, respectively. The median survival time for LD patients who received systemic treatment was 16.8 m, whereas for those who received local treatment (surgery), the median survival time was 10.1 m; the median survival time for ED patients who received systemic treatment was 7.4 m, compared with 5.8 m for those who received sole treatment (chemotherapy or radiotherapy). CONCLUSIONS: SCEC is a tumor characterized by high malignancy and early metastasis. Although our retrospective analysis cannot provide definitive conclusions on the optimal treatment modality for SCEC, however, our results suggest that systemic treatment combined with surgical resection plays a major role in the therapy of SCEC, systemic therapy may be an effective approach for the treatment of SCEC, and randomized, prospective, multicenter studies are needed to identify optimal treatment modalities for SCEC Springer-Verlag 2013-04-23 2013 /pmc/articles/PMC3674337/ /pubmed/23609140 http://dx.doi.org/10.1007/s11605-013-2204-7 Text en © The Author(s) 2013 https://creativecommons.org/licenses/by-nc/2.0/ Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
spellingShingle Original Article
Lu, Xu-jing
Luo, Ju-dong
Ling, Yang
Kong, Ying-Ze
Feng, Li-Li
Zhou, Jian
Wang, Feng
Management of Small Cell Carcinoma of Esophagus in China
title Management of Small Cell Carcinoma of Esophagus in China
title_full Management of Small Cell Carcinoma of Esophagus in China
title_fullStr Management of Small Cell Carcinoma of Esophagus in China
title_full_unstemmed Management of Small Cell Carcinoma of Esophagus in China
title_short Management of Small Cell Carcinoma of Esophagus in China
title_sort management of small cell carcinoma of esophagus in china
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3674337/
https://www.ncbi.nlm.nih.gov/pubmed/23609140
http://dx.doi.org/10.1007/s11605-013-2204-7
work_keys_str_mv AT luxujing managementofsmallcellcarcinomaofesophagusinchina
AT luojudong managementofsmallcellcarcinomaofesophagusinchina
AT lingyang managementofsmallcellcarcinomaofesophagusinchina
AT kongyingze managementofsmallcellcarcinomaofesophagusinchina
AT fenglili managementofsmallcellcarcinomaofesophagusinchina
AT zhoujian managementofsmallcellcarcinomaofesophagusinchina
AT wangfeng managementofsmallcellcarcinomaofesophagusinchina